These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7882383)

  • 1. Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells.
    Balemans LT; Steerenberg PA; Kremer BH; Koppenhagen FJ; De Mulder PH; Den Otter W
    Cancer Immunol Immunother; 1995 Feb; 40(2):125-31. PubMed ID: 7882383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.
    Balemans LT; Mattijssen V; Steerenberg PA; Van Driel BE; De Mulder PH; Den Otter W
    Cancer Immunol Immunother; 1993 Jul; 37(1):7-14. PubMed ID: 8513455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide.
    Balemans LT; Steerenberg PA; Koppenhagen FJ; Kremer BH; De Mulder PH; Claessen AM; Scheper RJ; Den Otter W
    Int J Cancer; 1994 Sep; 58(6):871-6. PubMed ID: 7927881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors.
    Mattijssen V; Balemans LT; Steerenberg PA; De Mulder PH
    Int J Cancer; 1992 Jul; 51(5):812-7. PubMed ID: 1612787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.
    Miller SD; Butler LD; Cleveland RP; Moorhead JW; Claman HN; Chiller JC
    Cell Immunol; 1983 Dec; 82(2):378-93. PubMed ID: 6197193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major-histocompatibility-complex-class-II-positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig.
    Steerenberg PA; De Jong WH; Geerse E; Beuvink A; Scheper RJ; Den Otter W; Ruitenberg EJ
    Cancer Immunol Immunother; 1990; 31(5):297-304. PubMed ID: 2376047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells.
    Woodcock J; Wofsy D; Eriksson E; Scott JH; Seaman WE
    Transplantation; 1986 Dec; 42(6):636-42. PubMed ID: 2947360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma.
    Claessen AM; Bloemena E; Bril H; Meijer CJ; Scheper RJ
    Cancer Res; 1992 May; 52(9):2440-6. PubMed ID: 1568214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.
    Fearon ER; Pardoll DM; Itaya T; Golumbek P; Levitsky HI; Simons JW; Karasuyama H; Vogelstein B; Frost P
    Cell; 1990 Feb; 60(3):397-403. PubMed ID: 2137372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of cytotoxic T lymphocytes requires at least two spleen cell-derived helper factors besides interleukin 2.
    Falk W; Männel DN; Dröge W
    J Immunol; 1983 May; 130(5):2214-8. PubMed ID: 6220085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major histocompatibility complex class II antigen expression on leucocyte subpopulations in the draining lymph node and tumour in the early phase of bacillus-Calmette-Guérin-induced tumour regression.
    Steerenberg PA; De Jong WH; Geerse E; De Graaf A; Scheper RJ; Den Otter W; Ruitenberg EJ
    Cancer Immunol Immunother; 1991; 33(3):189-97. PubMed ID: 1828389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma.
    de Jong WH; Teppema JS; Wagenaar SS; Paques M; Steerenberg PA; Ruitenberg EJ
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 50(3):249-69. PubMed ID: 2870577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
    Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
    Klarnet JP; Matis LA; Kern DE; Mizuno MT; Peace DJ; Thompson JA; Greenberg PD; Cheever MA
    J Immunol; 1987 Jun; 138(11):4012-7. PubMed ID: 3108381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
    Chen YM; Yang WK; Ting CC; Tsai WY; Yang DM; Whang-Peng J; Perng RP
    Chest; 1997 Oct; 112(4):960-6. PubMed ID: 9377959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
    J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations.
    Steerenberg PA; Geerse E; De Jong WH; Burger R; Scheper RJ; Den Otter W
    Cancer Immunol Immunother; 1991; 34(2):103-10. PubMed ID: 1760813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
    Ksander BR; Acevedo J; Streilein JW
    J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.